Physician profile
Kelley D Dasinger
NPI 1225336613
$1,486.16
in general payments reported to CMS, 2019-2025
14 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $282 · 2021: $58.27 · 2022: $196 · 2023: $87.89 · 2024: $74.53 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $596 · Entertainment: $14.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.21 |
| Entertainment | $14.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $201.41 | 2025 | Xdemvy |
| Coopervision INC. | $195.75 | 2019-2025 | Myday Contact Lens |
| Optovue, INC. | $194.09 | 2020 | |
| Sun Pharmaceutical Industries INC. | $186.71 | 2025 | |
| Bausch & Lomb Americas INC. | $173.26 | 2022-2024 | Infuse |
| Optos, INC. | $121.15 | 2019-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Lombart Brothers, INC. | $99.40 | 2019 | |
| Alcon Vision LLC | $86.18 | 2021-2025 | Dailies |
| Biotissue Holdings INC. | $66.05 | 2019-2024 | |
| Oyster Point Pharma, INC. | $61.40 | 2022-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $47.14 | 2019-2020 | |
| Dompe US, INC. | $23.61 | 2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $15.46 | 2023 | Acuvue |
| Maculogix, INC. | $14.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelley Dasinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.